Bioassay of XXXX for possible carcinogenicity.

@entity51225 @entity19 @entity5 @entity1557 @entity272 @entity35
A bioassay of practical-grade @entity51225 for possible carcinogenicity was conducted using Fischer 344 @entity35 and B6C3F1 @entity19 . @entity51225 was administered in the feed, at either of two concentrations, to groups of 50 male and 50 female animals of each species. For male and female @entity35 , the high and low time-weighted average dietary concentrations of @entity51225 were 0.02 and 0.008 percent, respectively. For male and female @entity19 , the high and low time-weighted average concentrations were 0.04 and 0.008 percent, respectively. After a 78-week period of compound administration, observation of the @entity35 continued for an additional 26 weeks and observation of the @entity19 continued for 13 additional weeks. For the chronic @entity35 bioassay, 25 @entity35 of each sex were placed on test as high dose controls, and 50 @entity35 of each sex served as the low dose controls. For the @entity19 , 50 males and 50 females were placed on test as controls for each of the high dose and low dose groups. In both species the survival in all groups was adequate for statistical analysis of late-appearing @entity5 . In the male @entity35 , a significantly increased incidence of @entity272 and subcutaneous tissue occurred in both the high and the low dose groups when compared to their respective controls. A statistically significant incidence of @entity1557 of the mammary gland occurred in the high dose female @entity35 . Among the @entity19 a variety of @entity5 was observed but none were considered to be associated with the dietary administration of @entity51225 . Under the conditions of this bioassay dietary administration of @entity51225 to Fischer 344 @entity35 induced @entity5 (i.e., @entity272 and subcutaneous tissue in males and @entity1557 of the mammary gland in females). No evidence was provided for the carcinogenicity of the compound in B6C3F1 @entity19 of either sex.
